McKesson MCK · NYSE
$977.49 +1.62% (+$15.61)
Summary
61 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 53% a year over the last 3 years.
- It earns 32 USD a year on every 100 USD of invested capital.
- It has raised its dividend 18 years in a row and pays out only 8.7% of profit.
- Analysts expect revenue to grow by 14% this fiscal year.
What to watch
- Out of every 100 USD of revenue, only 1.1 USD is left as net profit.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 24.9 USD for 1 USD of yearly profit. Over the last five years it was 26.7 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 9.2% a year over 5 years. Over the last 3 years it grew by 11% a year. For the next fiscal year analysts expect revenue to grow by 14%. Earnings per share grew by 53% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 96 USD
- Sales and administration 2.0 USD
- Taxes and other 0.5 USD
- Net profit 1.1 USD
Net profit, industry median (Medical - Distribution) 1.4 USD
Out of every 100 USD of revenue, 1.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.35%
- Paid out of profit
- 8.7%
- Raised in a row
- 18 years
You receive $3.40 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 25
- Hold 6
- Sell 0
Today's price within the analysts' price targets
The average target of $953 is 2.5% below today's price. 81% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- North American Pharmaceutical Segment 83%
- Oncology And Multispecialty Segment 12%
- Medical-Surgical Solutions Segment 2.9%
- Prescription Technology Solutions Segment 1.4%
- Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment 0.3%
By region
- UNITED STATES 83%
- International Segment 17%
North American Pharmaceutical Segment brings in 83% of revenue.
Segments in detail